ClinicalTrials.gg
CompletedNCT04385173Updated Oct 13, 2026

Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma

A Phase 1 interventional study of BP102 (B7-H3 CAR-T) in Recurrent Glioblastoma and Refractory Glioblastoma, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 1, Interventional, and Treatment

How we know

Updated Oct 13, 2026Now CompletedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 143 studies in Glioblastoma with a site in China — 74 open to participants now, 81 under way, 7 of them phase 3. Glioblastoma · China.

Enrollment
112th of 128
10 · median 36
Started
2022
with 17 others
Phase 1
46 of 143
23 open now
Registered
36th of 143
by date

Among the 143 studies in Glioblastoma with a site in China, this one is the 112th largest by enrollment of the 128 interventional ones that give a count, is one of 18 that started in 2022, is one of 46 in phase 1, and was the 36th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

74 of the 143 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Glioblastoma with a site in China, or all of them as a file.
02

Study summary

This is a pilot phase I, single-center, open-label, single-arm study to evaluate the feasibility, safety, tolerability, and preliminary efficacy of repeated intracranial infusions of BP102 in adults with recurrent or refractory glioblastoma. BP102 is an investigational autologous B7-H3 CAR-T cell therapy manufactured from each patient's peripheral blood mononuclear cells. B7-H3 CAR-T cells are designed to recognize B7-H3 expressed on glioblastoma cells. BP102 will be administered into the tumor cavity or cerebral ventricle through an implanted Ommaya reservoir. The study will also evaluate pharmacokinetic and pharmacodynamic characteristics, progression-free survival, and overall survival.

Read the detailed description

Background

  • B7-H3 is expressed in 70% of patients with glioblastoma
  • B7-H3 is not expressed in normal tissues especially not in central nervous system. Therefore, it is an attractive GBM target for CAR-T therapy
  • The investigators constructed a retroviral vector encoding a chimeric antigen receptor (CAR) targeting B7-H3, which can mediate CAR transfer into patient T cells with high efficiency.

Objectives

  • Primary Objective: To evaluate the feasibility, safety, and tolerability of intracranially administered BP102 in adult subjects with recurrent/refractory (R/R) glioblastoma (GBM).
  • Secondary Objectives:
  • To characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of BP102.
  • To assess the antitumor activity of BP102, including objective response rate (ORR) and duration of response.
  • To evaluate progression-free survival (PFS) and overall survival (OS) among subjects receiving BP102 treatment.
  • Exploratory Objective:
  • To evaluate the impacts of tumor and tumor microenvironment on the pharmacokinetics and pharmacodynamics of BP102.

Design This is a single-center, open-label, single-arm, pilot phase I study enrolling approximately 12 adults with recurrent or refractory glioblastoma. Participants will undergo leukapheresis and Ommaya reservoir implantation, followed by three planned intracranial infusions of autologous BP102 B7-H3 CAR-T cells at approximately 1- to 2-week intervals. Dose escalation will follow the protocol-defined intra-participant and inter-participant 3+3 rules, based on safety and dose-limiting toxicities. Participants who respond to BP102 may receive additional treatment cycles based on the investigator's risk-benefit assessment. Safety, antitumor activity, pharmacokinetics, pharmacodynamics, progression-free survival, and overall survival will be evaluated.

03

Conditions studied

  • Recurrent Glioblastoma
  • Refractory Glioblastoma

Browse trials for

Keywords

  • Chimeric Antigen Receptor (CAR)-T
  • Glioblastoma
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria:

  1. Age ≥18 years.
  2. Able and willing to provide written .
  3. Recurrent or glioblastoma with at enrollment.
  4. Glioblastoma confirmed by pathology, either from the current lesion or from the initial surgery, with pseudoprogression excluded by imaging. Available tumor tissue must be submitted for central laboratory analysis of B7-H3 expression.
  5. Intracranial tumor considered suitable for Ommaya reservoir implantation by the investigator.
  6. Performance Status (KPS) ≥70, confirmed before BP102 infusion.
  7. At least 6 weeks since completion of the last nitrosourea-based chemotherapy.
  8. At least 4 weeks since completion of the last temozolomide, other alkylating agent, other chemotherapy, or non-antiangiogenic targeted therapy. For participants whose most recent treatment was targeted therapy, screening may begin after a 2-week if treatment-related adverse events have returned to baseline.
  9. At least 4 weeks since the last dose of the antiangiogenic drug anlotinib, with a negative fecal occult blood test.
  10. Adequate organ function, confirmed before BP102 infusion, as follows:

    • White blood cell count ≥2,000/μL; ≥1,500/μL; count ≥100 × 10³/μL; ≥9.0 g/dL.
    • Serum creatinine ≤1.5 × the (ULN), or >30 mL/min/1.73 m² as calculated by the Cockcroft-Gault formula.
    • (ALT) ≤5 × ULN and total \<2.0 mg/dL, or \<3.0 mg/dL in participants with Gilbert syndrome or hepatic involvement by glioblastoma.
    • Less than Grade 1 dyspnea according to the (CTCAE), and oxygen saturation (SaO₂) ≥92% on room air.
    • (LVEF) ≥40%, assessed by echocardiography or multigated acquisition (MUGA) scan within 1 month before enrollment.
    • Normal coagulation function, including at least PT, , and INR.
  11. Adequate vascular access for leukapheresis.
  12. Absolute peripheral blood lymphocyte count ≥0.5 × 10⁹/L without mobilization.
  13. Participants of must agree to use highly effective for 1 year after BP102 infusion.
  14. Male participants with partners of childbearing potential must agree to use effective barrier contraception for 1 year after BP102 infusion.

Exclusion criteria

Exclusion Criteria

Participants meeting any of the following criteria will be excluded:

  1. History of another that has not been in remission for at least 2 years. The following are exempt from the 2-year requirement: non-melanoma skin cancer; completely resected Stage I tumors with a low risk of recurrence; treated localized prostate cancer; -confirmed cervical carcinoma in situ; or squamous intraepithelial lesions identified by a Pap smear.
  2. Requirement for concurrent anticancer therapy during BP102 infusion.
  3. Expected need for systemic for glioblastoma within 3 months.
  4. Active infection at screening, defined as hepatitis B virus DNA >1,000 copies by PCR, or active or (HIV) infection.
  5. Uncontrolled systemic fungal, bacterial, viral, or other infection.
  6. History within the previous 6 months of any of the following cardiovascular conditions: Class III or IV heart failure, coronary angioplasty or stenting, myocardial infarction, unstable angina, or other heart disease.
  7. Clinically significant psychiatric illness, either prior to or at screening.
  8. Low adrenocorticotropic hormone (ACTH) and thyroid hormone levels.
  9. disease.
  10. Pregnancy or breastfeeding.
  11. Any medical, psychological, family, social, or geographic condition that, in the investigator's judgment, could interfere with protocol compliance, or unwillingness or inability to comply with study procedures.
  12. Previous treatment with CAR-T cells or other genetically modified T-cell therapies.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    BP102 (B7-H3 CAR-T)

    Participants will receive three planned BP102 treatment cycles at approximately 1- to 2-week intervals. Dose escalation will follow the protocol-defined intra-participant and inter-participant 3+3 rules. Additional cycles may be administered to participants who respond to treatment based on the investigator's risk-benefit assessment.

    Drug: BP102 (B7-H3 CAR-T)

Interventions

  • DrugBP102Studies of BP102BP102 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BP102 is an autologous B7-H3 CAR-T cell product manufactured from the participant's peripheral blood mononuclear cells. It will be administered into the tumor cavity or cerebral ventricle through an implanted Ommaya reservoir.

06

What researchers measure

Primary outcomes

  1. Incidence and type of adverse events

    Number of Participants With Treatment-Related Adverse Events and Types of adverse events as Assessed by CTCAE v5.0

    Time frame: 12 weeks

  2. Maximum tolerated dose (MTD)

    The highest dose of B7-H3 CAR-T that does not cause targeted dose limiting toxicity

    Time frame: 12 weeks

  3. Overall survival (OS)

    Kaplan Meier methods will be used to estimate median OS

    Time frame: 2 years, up to 15 years if necessary

  4. Progression-free survival (PFS)

    Kaplan Meier methods will be used to estimate median PFS. Progression is defined by Response Assessment in Neuro-Oncology (RANO) criteria

    Time frame: 2 years, up to 15 years if necessary

Secondary outcomes

  1. The pharmacokinetics (PK) of B7-H3 CAR-T

    Peak Concentration (Cmax) of B7-H3 CAR-T in peripheral blood (PB) and cerebral spinal fluid (CSF)

    Time frame: 12 weeks

  2. The pharmacokinetics (PK) of B7-H3 CAR-T

    Area under the concentration versus time curve (AUC) of B7-H3 CAR-T in peripheral blood (PB) and cerebral spinal fluid (CSF)

    Time frame: 12 weeks

  3. Disease response (ORR, CR, PR, DOR)

    Objective Response Rate (ORR) will be assessed by comparison with baseline magnetic resonance imaging by RANO. Complete Response (CR) is disappearance of all measurable and non-measurable disease for at least 4 weeks. Partial Response (PR) is \>/= 50% decrease in lesions for at least 4 weeks. Duration of Response (DOR) is the time between the initial response to the treatment and subsequent disease progression.

    Time frame: 2 years, up to 15 years if necessary

Other outcomes

  1. Cytokine levels in PB and CSF

    The concentration of cytokines (IL-1, IL-2, IL-6, IL-10, TNF-α, IFN-γ) in PB and CSF

    Time frame: 12 weeks

  2. T cell phenotype

    The chimeric antigen receptor positive (CAR+) T cell and memory/effector T cell percentages and cell counts detected in peripheral blood (PB), and cerebral spinal fluid (CSF). Statistical and graphical methods will be used to describe persistence and expansion

    Time frame: 12 weeks

07

Study locations

1 site
  • the Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Sep 2026, 45 months.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's 45 months is close to that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Mar 2024 → Sep 2026 and completion May 2024 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2020
First posted
May 12, 2020
StartActual
Dec 1, 2022
Primary completionActual
Sep 1, 2026was Mar 2024
CompletionActual
Sep 1, 2026was May 2024
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 13, 2026
Primary completion
Mar 1, 2024→Sep 1, 2026 (actual)
Oct 13, 2026
Study completion
May 1, 2024→Sep 1, 2026 (actual)
Oct 13, 2026
Enrollment
12 (estimated)→10 (actual)
Oct 13, 2026
Eligibility
Criteria largely rewritten (66 changes)
What changed in the criteria
Inclusion criteria
  • RemovedDocumented informed consent of the participant and/or legally authorized representative.
  • RemovedHistologically confirmed diagnosis of World Health Organization (WHO) classification grade IV glioblastoma (GBM).
  • RemovedClinical Pathology confirms B7-H3 positive tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score >= 50).
  • RemovedRelapsed/refractory disease confirmed by radiographic evidence after standard therapy.
  • RemovedSuitable for the surgery of the placement of the Ommaya catheter.
  • RemovedEastern Cooperative Oncology Group (ECOG) =0 or 1 (need to be confirmed before intratumoral or intracerebroventricular injection)
  • Removed>= 8 weeks after completion of front-line radiation therapy
  • Removed>= 6 weeks after completion of nitrourea chemotherapy
  • Removed>= 14 days after completion of Temozolomide or other chemotherapy
  • Removed2 weeks of wash-out time after completion of targeted therapy with related adverse events (AE) on baseline (4 weeks for Bevacizumab).
  • RemovedPatients with other chronic AEs are in the investigator's judgement
  • RemovedBlood cell count: White blood count (WBC) >= 2000/μL;Neutrophil count >= 1500/μL;Platelets >= 100 x 103/μL;Hemoglobin >= 9.0 g/dL
  • AddedParticipants must meet all of the following criteria:
  • AddedAge ≥18 years.
  • AddedAble and willing to provide written informed consent.
  • AddedRecurrent or refractory glioblastoma with measurable disease at enrollment.
  • AddedGlioblastoma confirmed by pathology, either from the current lesion or from the initial surgery, with pseudoprogression excluded by imaging. Available tumor tissue must be submitted for central laboratory analysis of B7-H3 expression.
  • AddedIntracranial tumor considered suitable for Ommaya reservoir implantation by the investigator.
  • AddedKarnofsky Performance Status (KPS) ≥70, confirmed before BP102 infusion.
  • AddedAt least 6 weeks since completion of the last nitrosourea-based chemotherapy.
  • AddedAt least 4 weeks since completion of the last temozolomide, other alkylating agent, other chemotherapy, or non-antiangiogenic targeted therapy. For participants whose most recent treatment was targeted therapy, screening may begin after a 2-week washout period if treatment-related adverse events have returned to baseline.
  • AddedAt least 4 weeks since the last dose of the antiangiogenic drug anlotinib, with a negative fecal occult blood test.
  • AddedAdequate organ function, confirmed before BP102 infusion, as follows:
  • AddedWhite blood cell count ≥2,000/μL; absolute neutrophil count ≥1,500/μL; platelet count ≥100 × 10³/μL; hemoglobin ≥9.0 g/dL.
  • EditedSerum Creatinine <= creatinine ≤1.5 × the upper limit of normal (ULN), or Creatinine Clearance Rate (Cockcroft and Gault)creatinine clearance > 30 mL/min/1.73 m2m² as calculated by the Cockcroft-Gault formula.
  • EditedAlanine Transaminaseaminotransferase (ALT) <= 5≤5 × ULN and total bilirubin < 2.0mg0 mg/dL, or <3.0 mg/dL in participants with Gilbert syndrome or hepatic involvement by glioblastoma.
  • ChangedBefore Lung function: Oxygen (O2) saturation >= 92% on room air and < CTCAE grade 1 dyspneaNow Less than Grade 1 dyspnea according to the Common Terminology Criteria for Adverse Events (CTCAE), and oxygen saturation (SaO₂) ≥92% on room air.
  • EditedHeart function: Left ventricular ejection fraction (LVEF) >= ≥40%, assessed by echocardiography or multigated acquisition (MUGA) scan or echocardiogramwithin 1 month before enrollment.
  • RemovedNormal coagulation function: prothrombin time (PT),activated partial thromboplastin time (APTT) and international normalized ratio (INR)
  • RemovedGood blood vessel condition for leukapheresis
  • RemovedWomen of childbearing potential (WOCBP): negative urine or serum pregnancy test
  • RemovedAgreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity within one year after B7-H3 CAR-T infusion
  • AddedNormal coagulation function, including at least PT, APTT, and INR.
  • AddedAdequate vascular access for leukapheresis.
  • AddedAbsolute peripheral blood lymphocyte count ≥0.5 × 10⁹/L without mobilization.
  • AddedParticipants of childbearing potential must agree to use highly effective contraception for 1 year after BP102 infusion.
  • AddedMale participants with partners of childbearing potential must agree to use effective barrier contraception for 1 year after BP102 infusion.
Exclusion criteria
  • RemovedOther active malignancy in the past 2 years except non-melanoma skin cancer, completely surgical removed low grade tumor, posttherapeutic limited-stage prostate cancer, biopsy confirmed in situ cervical carcinoma, PAP test confirmed squamous intraepithelial lesions
  • RemovedParticipant is undergoing or planning to take other anti-tumor therapies
  • RemovedParticipant is systematic steroid-dependent, or is expecting to be treated with systematic steroid

…and 26 more changes, on the record history on ClinicalTrials.gov ↗

Oct 13, 2026
Interventions
Changed B7-H3 CAR-T→BP102 (B7-H3 CAR-T). Removed Drug: Temozolomide. Arm changed B7-H3 CAR-T→BP102 (B7-H3 CAR-T)
Oct 13, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionIncidence and type of adverse events: how it is measured was reworded
Oct 13, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Status unknown→Completed
    Primary completion Mar 1, 2024→Sep 1, 2026 (now actual)
    Study completion May 1, 2024→Sep 1, 2026 (now actual)
    Enrollment 12 (estimated)→10 (actual)
    Eligibility Criteria largely rewritten (66 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedDocumented informed consent of the participant and/or legally authorized representative.
    • RemovedHistologically confirmed diagnosis of World Health Organization (WHO) classification grade IV glioblastoma (GBM).
    • RemovedClinical Pathology confirms B7-H3 positive tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score >= 50).
    • RemovedRelapsed/refractory disease confirmed by radiographic evidence after standard therapy.
    • RemovedSuitable for the surgery of the placement of the Ommaya catheter.
    • RemovedEastern Cooperative Oncology Group (ECOG) =0 or 1 (need to be confirmed before intratumoral or intracerebroventricular injection)
    • Removed>= 8 weeks after completion of front-line radiation therapy
    • Removed>= 6 weeks after completion of nitrourea chemotherapy
    • Removed>= 14 days after completion of Temozolomide or other chemotherapy
    • Removed2 weeks of wash-out time after completion of targeted therapy with related adverse events (AE) on baseline (4 weeks for Bevacizumab).
    • RemovedPatients with other chronic AEs are in the investigator's judgement
    • RemovedBlood cell count: White blood count (WBC) >= 2000/μL;Neutrophil count >= 1500/μL;Platelets >= 100 x 103/μL;Hemoglobin >= 9.0 g/dL
    • AddedParticipants must meet all of the following criteria:
    • AddedAge ≥18 years.
    • AddedAble and willing to provide written informed consent.
    • AddedRecurrent or refractory glioblastoma with measurable disease at enrollment.
    • AddedGlioblastoma confirmed by pathology, either from the current lesion or from the initial surgery, with pseudoprogression excluded by imaging. Available tumor tissue must be submitted for central laboratory analysis of B7-H3 expression.
    • AddedIntracranial tumor considered suitable for Ommaya reservoir implantation by the investigator.
    • AddedKarnofsky Performance Status (KPS) ≥70, confirmed before BP102 infusion.
    • AddedAt least 6 weeks since completion of the last nitrosourea-based chemotherapy.
    • AddedAt least 4 weeks since completion of the last temozolomide, other alkylating agent, other chemotherapy, or non-antiangiogenic targeted therapy. For participants whose most recent treatment was targeted therapy, screening may begin after a 2-week washout period if treatment-related adverse events have returned to baseline.
    • AddedAt least 4 weeks since the last dose of the antiangiogenic drug anlotinib, with a negative fecal occult blood test.
    • AddedAdequate organ function, confirmed before BP102 infusion, as follows:
    • AddedWhite blood cell count ≥2,000/μL; absolute neutrophil count ≥1,500/μL; platelet count ≥100 × 10³/μL; hemoglobin ≥9.0 g/dL.
    • EditedSerum Creatinine <= creatinine ≤1.5 × the upper limit of normal (ULN), or Creatinine Clearance Rate (Cockcroft and Gault)creatinine clearance > 30 mL/min/1.73 m2m² as calculated by the Cockcroft-Gault formula.
    • EditedAlanine Transaminaseaminotransferase (ALT) <= 5≤5 × ULN and total bilirubin < 2.0mg0 mg/dL, or <3.0 mg/dL in participants with Gilbert syndrome or hepatic involvement by glioblastoma.
    • ChangedBefore Lung function: Oxygen (O2) saturation >= 92% on room air and < CTCAE grade 1 dyspneaNow Less than Grade 1 dyspnea according to the Common Terminology Criteria for Adverse Events (CTCAE), and oxygen saturation (SaO₂) ≥92% on room air.
    • EditedHeart function: Left ventricular ejection fraction (LVEF) >= ≥40%, assessed by echocardiography or multigated acquisition (MUGA) scan or echocardiogramwithin 1 month before enrollment.
    • RemovedNormal coagulation function: prothrombin time (PT),activated partial thromboplastin time (APTT) and international normalized ratio (INR)
    • RemovedGood blood vessel condition for leukapheresis
    • RemovedWomen of childbearing potential (WOCBP): negative urine or serum pregnancy test
    • RemovedAgreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity within one year after B7-H3 CAR-T infusion
    • AddedNormal coagulation function, including at least PT, APTT, and INR.
    • AddedAdequate vascular access for leukapheresis.
    • AddedAbsolute peripheral blood lymphocyte count ≥0.5 × 10⁹/L without mobilization.
    • AddedParticipants of childbearing potential must agree to use highly effective contraception for 1 year after BP102 infusion.
    • AddedMale participants with partners of childbearing potential must agree to use effective barrier contraception for 1 year after BP102 infusion.
    Exclusion criteria
    • RemovedOther active malignancy in the past 2 years except non-melanoma skin cancer, completely surgical removed low grade tumor, posttherapeutic limited-stage prostate cancer, biopsy confirmed in situ cervical carcinoma, PAP test confirmed squamous intraepithelial lesions
    • RemovedParticipant is undergoing or planning to take other anti-tumor therapies
    • RemovedParticipant is systematic steroid-dependent, or is expecting to be treated with systematic steroid

    …and 26 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionIncidence and type of adverse events: how it is measured was reworded
    Interventions Changed B7-H3 CAR-T→BP102 (B7-H3 CAR-T). Removed Drug: Temozolomide. Arm changed B7-H3 CAR-T→BP102 (B7-H3 CAR-T)
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    + 6 other changes: identifiers, verification date, description, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04385173
Collaborators
BoYuan RunSheng Pharma (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
May 12, 2020
Start date
Dec 1, 2022
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BP102

Start the discussion